An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate. (Q34954063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

Constantino Carlos Reyes-Aldasoro

20 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

7

G M Tozer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

L J Williams

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

M Fisher

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

S Akerman

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

C Kanthou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Pharmacology

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

4902-4913

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

20 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Animal research: reporting in vivo experiments: the ARRIVE guidelines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Guidelines for the welfare and use of animals in cancer research

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Organizing the cell cortex: the role of ERM proteins

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Adhesion proteins meet receptors: a common theme?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Tumour vascular disrupting agents: combating treatment resistance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Tumour targeting by microtubule-depolymerizing vascular disrupting agents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Disrupting tumour blood vessels

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Synergy between vascular targeting agents and antibody-directed therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Activation of Rhoa and ROCK are essential for detachment of migrating leukocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.

8 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4294113

ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis

26 October 2018

1 reference

https://api.crossref.org/works/10.1111%2FBPH.12817

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Control of differentiation in human colorectal carcinoma cell lines: epithelial-mesenchymal interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/24930520

12 December 2020

Identifiers

DOI

10.1111/BPH.12817

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

24930520

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930520%20AND%20SRC:MED&resulttype=core&format=json